


## REMARKS

In the Office Action, the Examiner has required Applicants to further elect a single invention among Groups I – III

Applicants hereby elect, without traverse, Group I, claims 1-4 and 7 drawn to compounds of formula (I).

The Examiner further required an election of species if Group (1) is elected. Applicants hereby elect the compound of example I1: 3R)-Benzyloxymethyl-2(S)-(4-methoxy-phenyl)-pent-4-enoic acid.




It is understood that upon allowance of a generic claim, Applicants will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim.

Applicants request rejoinder of the method claims of commensurate scope to the composition of matter claims upon allowance of claims directed to the elected invention, e.g., Applicants respectfully request rejoinder of the subject matter corresponding to Groups II and III upon allowance of the claims embodying the elected invention

Applicants respectfully request that the remarks made herein be entered and made of record in the file history of the present application. If any issues remain in connection herewith, the Examiner is respectfully invited to telephone the undersigned to discuss the same.

Respectfully submitted,

Novartis Institutes for BioMedical Research, Inc.  
400 Technology Square  
Cambridge, MA 02139  
(617) 871-3027

  
\_\_\_\_\_  
Mei L. Benni  
Attorney for Applicants  
Reg. No. 45,470

Date: November 17, 2008